Key barriers include misdiagnosis, insufficient gMG knowledge among healthcare providers, and limited access to specialists, ...

Abstract: Ptosis of the eyelids is a common condition with a myriad of causes. Its management depends on the underlying cause, which can be challenging to diagnose in some cases. Current diagnosis ...

A couple has decorated their house in Christmas lights in the hopes of fundraising for a cure to a "horrible" illness.

Earlier this week, argenx SE halted its Phase 3 UplighTED trials of subcutaneous efgartigimod for moderate to severe thyroid eye disease after an Independent Data Monitoring Committee recommended ...

Kyverna Therapeutics stock upgraded to Strong Buy after positive phase 2 results for miv-cel in SPS and MG. Read the latest ...

Vyvgart, an FcRn inhibitor already approved for generalized myasthenia gravis, is also being tested in myositis, Sjögren’s ...

While argenx has been able to demonstrate the merit of its FcRn drug Vyvgart in multiple autoimmune indications, not every ...

Investing.com -- argenx stock fell 8.4% on Monday after the global immunology company announced it will discontinue its Phase 3 UplighTED studies evaluating efgartigimod SC in adults with thyroid eye ...

AM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today ...

Immunovant shifts primary focus to IMVT-1402, a next-generation anti-FcRn, targeting Graves' Disease with potential ...

Amgen secures FDA approval for Uplinza in generalized myasthenia gravis, giving antibody-positive adults a targeted treatment option supported by Phase 3 data.

Amid a swell of regulatory successes in the myasthenia gravis arena this decade, Amgen is wading into the fray with a new indication for its monoclonal antibody Uplizna. | On Thursday, the FDA green ...